GLP1R and atherosclerosis: Patients with HTG often have DM and pharmacologic therapies aimed at treating DM, such as glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium glucose transporter-2 inhibitors (SGLT2i), and metformin, can enable weight loss, improve glycemic control, lower TG, and reduce ASCVD risk.